Coronary thrombolysis with recombinant human tissue-type plasminogen activator. 1984

H K Gold, and J T Fallon, and T Yasuda, and R C Leinbach, and B A Khaw, and J B Newell, and J L Guerrero, and F M Vislosky, and C F Hoyng, and E Grossbard

The thrombolytic potency and myocardial infarct--sparing potential of recombinant tissue-type plasminogen activator (rt-PA) were studied in electrocardiographically monitored, open-chest, anesthetized dogs. Localized coronary thrombosis was produced in the left anterior descending artery by endothelial injury and instillation of thrombin and fresh blood. After 2 hr of stable thrombotic occlusion, rt-PA was infused intravenously. At a dose of 4.3 micrograms/kg/min, time to reperfusion was greater than 40 min (n = 3). However, at higher infusion rates a linear, dose-dependent time to coronary reperfusion was obtained (r = .88): at 10 micrograms/kg/min reperfusion occurred after 31 +/- 2 min (n = 3), at 15 micrograms/kg/min it was at 26 +/- 7 min (n = 4), and at 25 micrograms/kg/min, lysis was accomplished within 13 +/- 3 min (n = 3). Thrombolysis was not associated with alterations in either plasma hemostatic factors (fibrinogen, plasminogen, and alpha 2-antiplasmin) or in systemic blood pressures. Epicardial electrographic measurements revealed a significant reduction in ST elevation in all reperfused hearts. A randomized, blinded study was also carried out with 15 micrograms/kg/min of rt-PA saline in 18 dogs with 30 min of coronary thrombosis. Reperfusion in the treated group occurred after 28 +/- 3 min. No evidence of thrombolysis was noted in the saline-treated group within 240 min. Size of myocardial infarction was determined by triphenyl tetrazolium chloride staining and planimetry. Infarction involved 2.5 +/- 0.5% of the left ventricular wall in the group receiving rt-PA, but 16 +/- 3% of the left ventricle in the saline-treated group (p = .001). It is concluded that intravenous infusion of rt-PA results in rapid, dose-dependent coronary thrombolysis without systemic fibrinolytic activation and that early lysis of coronary thrombi is associated with substantial salvage of myocardial tissue.

UI MeSH Term Description Entries
D009203 Myocardial Infarction NECROSIS of the MYOCARDIUM caused by an obstruction of the blood supply to the heart (CORONARY CIRCULATION). Cardiovascular Stroke,Heart Attack,Myocardial Infarct,Cardiovascular Strokes,Heart Attacks,Infarct, Myocardial,Infarction, Myocardial,Infarctions, Myocardial,Infarcts, Myocardial,Myocardial Infarctions,Myocardial Infarcts,Stroke, Cardiovascular,Strokes, Cardiovascular
D010958 Plasminogen Precursor of plasmin (FIBRINOLYSIN). It is a single-chain beta-globulin of molecular weight 80-90,000 found mostly in association with fibrinogen in plasma; plasminogen activators change it to fibrinolysin. It is used in wound debriding and has been investigated as a thrombolytic agent. Profibrinolysin,Glu-Plasminogen,Glutamic Acid 1-Plasminogen,Glutamyl Plasminogen,1-Plasminogen, Glutamic Acid,Glu Plasminogen,Glutamic Acid 1 Plasminogen,Plasminogen, Glutamyl
D010960 Plasminogen Activators A heterogeneous group of proteolytic enzymes that convert PLASMINOGEN to FIBRINOLYSIN. They are concentrated in the lysosomes of most cells and in the vascular endothelium, particularly in the vessels of the microcirculation. Extrinsic Plasminogen Activators,Plasminogen Activator,Uterine-Tissue Plasminogen Activator,Uterine Tissue Plasminogen Activator
D003327 Coronary Disease An imbalance between myocardial functional requirements and the capacity of the CORONARY VESSELS to supply sufficient blood flow. It is a form of MYOCARDIAL ISCHEMIA (insufficient blood supply to the heart muscle) caused by a decreased capacity of the coronary vessels. Coronary Heart Disease,Coronary Diseases,Coronary Heart Diseases,Disease, Coronary,Disease, Coronary Heart,Diseases, Coronary,Diseases, Coronary Heart,Heart Disease, Coronary,Heart Diseases, Coronary
D004195 Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases. Animal Disease Model,Animal Disease Models,Disease Model, Animal
D004285 Dogs The domestic dog, Canis familiaris, comprising about 400 breeds, of the carnivore family CANIDAE. They are worldwide in distribution and live in association with people. (Walker's Mammals of the World, 5th ed, p1065) Canis familiaris,Dog
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004562 Electrocardiography Recording of the moment-to-moment electromotive forces of the HEART as projected onto various sites on the body's surface, delineated as a scalar function of time. The recording is monitored by a tracing on slow moving chart paper or by observing it on a cardioscope, which is a CATHODE RAY TUBE DISPLAY. 12-Lead ECG,12-Lead EKG,12-Lead Electrocardiography,Cardiography,ECG,EKG,Electrocardiogram,Electrocardiograph,12 Lead ECG,12 Lead EKG,12 Lead Electrocardiography,12-Lead ECGs,12-Lead EKGs,12-Lead Electrocardiographies,Cardiographies,ECG, 12-Lead,EKG, 12-Lead,Electrocardiograms,Electrocardiographies, 12-Lead,Electrocardiographs,Electrocardiography, 12-Lead
D005340 Fibrinogen Plasma glycoprotein clotted by thrombin, composed of a dimer of three non-identical pairs of polypeptide chains (alpha, beta, gamma) held together by disulfide bonds. Fibrinogen clotting is a sol-gel change involving complex molecular arrangements: whereas fibrinogen is cleaved by thrombin to form polypeptides A and B, the proteolytic action of other enzymes yields different fibrinogen degradation products. Coagulation Factor I,Factor I,Blood Coagulation Factor I,gamma-Fibrinogen,Factor I, Coagulation,gamma Fibrinogen
D005342 Fibrinolysis The natural enzymatic dissolution of FIBRIN. Fibrinolyses

Related Publications

H K Gold, and J T Fallon, and T Yasuda, and R C Leinbach, and B A Khaw, and J B Newell, and J L Guerrero, and F M Vislosky, and C F Hoyng, and E Grossbard
April 1990, Annals of internal medicine,
H K Gold, and J T Fallon, and T Yasuda, and R C Leinbach, and B A Khaw, and J B Newell, and J L Guerrero, and F M Vislosky, and C F Hoyng, and E Grossbard
February 1987, Cardiology clinics,
H K Gold, and J T Fallon, and T Yasuda, and R C Leinbach, and B A Khaw, and J B Newell, and J L Guerrero, and F M Vislosky, and C F Hoyng, and E Grossbard
June 1984, The New England journal of medicine,
H K Gold, and J T Fallon, and T Yasuda, and R C Leinbach, and B A Khaw, and J B Newell, and J L Guerrero, and F M Vislosky, and C F Hoyng, and E Grossbard
March 1984, Circulation,
H K Gold, and J T Fallon, and T Yasuda, and R C Leinbach, and B A Khaw, and J B Newell, and J L Guerrero, and F M Vislosky, and C F Hoyng, and E Grossbard
December 1984, Circulation,
H K Gold, and J T Fallon, and T Yasuda, and R C Leinbach, and B A Khaw, and J B Newell, and J L Guerrero, and F M Vislosky, and C F Hoyng, and E Grossbard
April 1988, Thrombosis and haemostasis,
H K Gold, and J T Fallon, and T Yasuda, and R C Leinbach, and B A Khaw, and J B Newell, and J L Guerrero, and F M Vislosky, and C F Hoyng, and E Grossbard
December 1985, Annals of internal medicine,
H K Gold, and J T Fallon, and T Yasuda, and R C Leinbach, and B A Khaw, and J B Newell, and J L Guerrero, and F M Vislosky, and C F Hoyng, and E Grossbard
December 1984, Texas Heart Institute journal,
H K Gold, and J T Fallon, and T Yasuda, and R C Leinbach, and B A Khaw, and J B Newell, and J L Guerrero, and F M Vislosky, and C F Hoyng, and E Grossbard
June 1983, Science (New York, N.Y.),
H K Gold, and J T Fallon, and T Yasuda, and R C Leinbach, and B A Khaw, and J B Newell, and J L Guerrero, and F M Vislosky, and C F Hoyng, and E Grossbard
November 1985, European heart journal,
Copied contents to your clipboard!